Anesthesia & Respiratory Devices Market Value Predicted To Reach US$ 43.7 Billion By 2027: Acumen Research And Consulting
March 31, 2021 12:24 ET
|
Acumen Research and Consulting
LOS ANGELES, March 31, 2021 (GLOBE NEWSWIRE) -- The Global Anesthesia & Respiratory Devices Market is expected to grow at a CAGR of around 6.5% from 2020 to 2027 and reach the market value of...
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
November 19, 2020 16:30 ET
|
Novartis International AG
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other...
Vitalograph Launch Powerful New In2itive e-Diary for Global Clinical Trials
October 14, 2020 09:00 ET
|
Vitalograph
Next generation eCOA device with integrated respiratory assessment Vitalograph are delighted to announce that their most powerful ever In2itive...
Grey Cloak Tech Inc. Launches Customer Relationship Management (CRM) Program to Increase Sales and Retention
October 08, 2020 08:30 ET
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary...
Grey Cloak Tech Inc. Introduces ‘Clinical IMMUNE™’ to Combat Respiratory Symptoms
October 06, 2020 08:30 ET
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – name change pending to Healthy Extracts Inc.), today announces that its BergaMet NA subsidiary has...
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
September 07, 2020 01:15 ET
|
Novartis International AG
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
July 07, 2020 01:15 ET
|
Novartis International AG
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with...
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
June 29, 2020 02:45 ET
|
Novartis International AG
Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for...
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
June 05, 2020 01:15 ET
|
Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
May 18, 2020 07:15 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...